[1]Gallage S, et al. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1. Cell Metab. 2024 May 2:S1550-4131(24)00135-9. doi: 10.1016/j.cmet.2024.04.015. Epub ahead of print. PMID: 38718791.
[2]刘傲雪,周翔海,张秀英,等.非酒精性脂肪肝的危险因素探讨[J].中国临床医生杂志,2021,49(02):165-169.
[3]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 中华糖尿病杂志,2010,2(1):15-19.
[4]胡漂,孔东明,朱仲鑫.1990—2019年中国人群非酒精性脂肪肝疾病负担分析[J].中国预防医学杂志,2022,23(04):260-264.DOI:10.16506/j.1009-6639.2022.04.004.
[5]DOI:10.3760/cma.j.issn.1674-5809.2010.01.006
[6] Intermittent fasting protects against liver inflammation and liver cancer. Retrieved May 8, 2024 from https://www.eurekalert.org/news-releases/1043801
[7]Younossi ZM, Zelber-Sagi S, Henry L, et al. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023 Jul 4. doi: 10.1038/s41575-023-00800-4.
[8]Zhou XD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023 Aug;17(4):773-791. doi: 10.1007/s12072-023-10543-8. Epub 2023 May 19. PMID: 37204656; PMCID: PMC10198034.
[9]《中国脂肪肝防治指南》